View Older Stories

Jul 24, 2025 09:01AM Applied DNA receives $600,000 follow-on order for cancer diagnostic use

Jul 24, 2025 09:00AM Applied DNA Announces New Follow-On LineaDNA Order from Global IVD Manufacturer for Use in Cancer Diagnostic Application

Jul 7, 2025 09:02AM Applied DNA Sciences (APDN) regains Nasdaq compliance with minimum bid price rules

Jul 7, 2025 09:00AM Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements

Jun 30, 2025 09:02AM Applied DNA Sciences (APDN) Cuts 27% Staff, Consolidates Operations Behind LineaRx

Jun 30, 2025 09:00AM Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx

Jun 17, 2025 04:10PM Applied DNA Sciences (APDN) Announces Retirement of Chairperson and CEO Dr. James A. Hayward

Jun 17, 2025 04:10PM Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward

Jun 16, 2025 09:00AM Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August

May 29, 2025 04:05PM Applied DNA Reschedules Intra-Quarter Webcast and Investor Update Call to June 17

May 29, 2025 08:00AM Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025

May 15, 2025 06:38PM Applied DNA Sciences (APDN) Misses Q2 EPS by 1535c

May 15, 2025 04:05PM Applied DNA Reports Second Quarter Fiscal 2025 Financial Results

May 14, 2025 11:30AM Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3

Apr 21, 2025 09:02AM Applied DNA Sciences' (APDN) LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA

Apr 21, 2025 09:00AM Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA

Apr 8, 2025 09:04AM Applied DNA Sciences (APDN) Regains Nasdaq Compliance

Apr 8, 2025 09:00AM Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 1, 2025 09:47AM Applied DNA Sciences (APDN) Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics

Apr 1, 2025 09:45AM Applied DNA Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement

Mar 26, 2025 09:03AM Applied DNA Sciences (APDN) Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A Laboratory-Developed Test

Mar 26, 2025 09:00AM Applied DNA Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A Laboratory-Developed Test

Mar 12, 2025 08:05AM Applied DNA Sciences (APDN) Announces 1-For-50 Reverse Stock Split Effective March 14, 2025

Mar 12, 2025 08:00AM Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025

Feb 13, 2025 04:03PM Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress

Feb 12, 2025 12:00PM Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025

Feb 11, 2025 08:30AM Applied DNA Reminds Shareholders to Vote Ahead of Special Meeting on February 14

Jan 10, 2025 09:00AM Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

Jan 8, 2025 04:30PM Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter

Dec 18, 2024 09:00AM Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

Dec 17, 2024 04:05PM Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines

Dec 16, 2024 10:00AM Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GM

Oct 30, 2024 07:17AM Applied DNA Sciences (APDN) Prices $6.5M Share Offering at $0.32/sh

Oct 30, 2024 07:15AM Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement

Oct 15, 2024 10:30AM Applied DNA to Participate in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16

Sep 18, 2024 09:02AM Applied DNA Sciences (APDN) Regains Nasdaq Compliance

Sep 18, 2024 09:00AM Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 17, 2024 09:15AM Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit

Sep 17, 2024 09:03AM Applied DNA Sciences (APDN) Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application

Sep 17, 2024 09:00AM Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application

Sep 11, 2024 09:03AM Applied DNA Sciences (APDN) Launches Mpox Clade I and Clade II Testing Service

Sep 11, 2024 09:00AM Applied DNA Launches Mpox Clade I and Clade II Testing Service

Sep 4, 2024 09:04AM Applied DNA Sciences (APDN) Selected by LRQA for Isotopic Testing Pilot Project in Pakistan

Sep 4, 2024 09:00AM Applied DNA Selected by LRQA for Isotopic Testing Pilot Project in Pakistan

Aug 23, 2024 09:05AM Applied DNA Sciences (APDN) Submits Validation Package to New York State Department of Health to Expand Linea Mpox Virus 1.0 Assay to Mpox Clade I

Aug 23, 2024 09:00AM Applied DNA Submits Validation Package to New York State Department of Health to Expand Linea Mpox Virus 1.0 Assay to Mpox Clade I

Aug 19, 2024 03:27PM Applied DNA Sciences (APDN) To Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I

Aug 19, 2024 03:25PM Applied DNA To Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I

Aug 8, 2024 07:32PM Applied DNA Sciences (APDN) Tops Q3 EPS by 417c

Aug 8, 2024 04:10PM Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results

View Older Stories